Nilotinib Clonmel

Nilotinib, the active ingredient in Nilotinib Clonmel, is a tyrosine kinase inhibitor presented as a tablet for oral use. It selectively targets BCR‑ABL positive leukemic cells and is used to treat chronic myeloid leukemia in adult patients, approved in the European Union for Philadelphia chromosome‑positive disease.

GNH USA supplies Nilotinib Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Nilotinib is indicated for the treatment of chronic myeloid leukemia, a BCR‑ABL driven hematologic malignancy.

- Chronic myeloid leukemia (chronic phase): reduces disease progression and improves survival in patients with Philadelphia chromosome‑positive disease. - Chronic myeloid leukemia (accelerated phase): achieves cytogenetic responses and delays transformation to blast phase. - Chronic myeloid leukemia (blast phase): provides disease control when combined with other therapies in advanced disease.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Rash - Headache - Fatigue - Elevated liver enzymes (ALT, AST)

Serious or Rare Side Effects: - Cardiovascular events (ischemic heart disease, arterial occlusion) - QT interval prolongation leading to arrhythmia - Pancreatitis - Severe hepatotoxicity - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Pulmonary arterial hypertension

When prescribing Nilotinib, clinicians should consider several safety measures and monitoring requirements.

- Cardiac assessment: evaluate baseline ECG and monitor for QT prolongation. - Hepatic function: check liver enzymes before and during therapy. - Pancreatic enzymes: monitor amylase and lipase periodically. - Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Nilotinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise nilotinib levels → risk of toxicity. - St. John’s wort (CYP3A4 inducer): may lower nilotinib exposure → loss of efficacy. - Antacids containing aluminum or magnesium: reduce absorption → decrease effectiveness.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors (omeprazole): may modestly reduce absorption. - CYP3A4 inducers (rifampin, carbamazepine): may decrease plasma levels. - Statins metabolized by CYP3A4 (simvastatin, lovastatin): increased risk of myopathy.